Cited 0 times in Scipus Cited Count

Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL

DC Field Value Language
dc.contributor.authorCha, HY-
dc.contributor.authorLee, BS-
dc.contributor.authorChang, JW-
dc.contributor.authorPark, JK-
dc.contributor.authorHan, JH-
dc.contributor.authorKim, YS-
dc.contributor.authorShin, YS-
dc.contributor.authorByeon, HK-
dc.contributor.authorKim, CH-
dc.date.accessioned2018-05-04T00:24:31Z-
dc.date.available2018-05-04T00:24:31Z-
dc.date.issued2016-
dc.identifier.issn0304-3835-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14868-
dc.description.abstractTumor necrosis factor-related apoptosis-inducing ligand (TRAIL) represents an effective agent for the treatment of many cancers, though the majority of thyroid cancers are found to be resistant. Therefore it would be necessary to identify agents capable of increasing the sensitivity of these cancers to TRAIL-mediated cell death. Here, we examined the therapeutic effect and its underlying mechanism of combination treatment of TRAIL and histone deacetylase inhibitor, Valproic acid (VPA) in vitro using human papillary thyroid cancer (PTC) cells and in vivo using an orthotopic mouse model of PTC. TRAIL-VPA combination therapy synergistically induced apoptotic cell death in TRAIL-resistant PTC through caspase activation. In addition, downregulation of antioxidant transcription factor, Nrf2 by co-treatment of TRAIL-VPA induces cell death via suppression of Bcl-xL in vitro and in vivo: these effects were further enhanced following siRNA inhibition of these proteins in combination with TRAIL or TRAIL-VPA. Taken together, VPA sensitized TRAIL-resistant PTC cells to apoptotic cell death through involvement of Nrf2 and Bcl-xL. Thus, the combination of VPA and TRAIL may be a promising therapy for TRAIL-resistant PTC.-
dc.language.isoen-
dc.subject.MESHAnimals-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHApoptosis-
dc.subject.MESHCarcinoma-
dc.subject.MESHCarcinoma, Papillary-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Survival-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHDown-Regulation-
dc.subject.MESHDrug Resistance, Neoplasm-
dc.subject.MESHDrug Synergism-
dc.subject.MESHHistone Deacetylase Inhibitors-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMice, Inbred BALB C-
dc.subject.MESHMice, Nude-
dc.subject.MESHNF-E2-Related Factor 2-
dc.subject.MESHRNA Interference-
dc.subject.MESHSignal Transduction-
dc.subject.MESHTNF-Related Apoptosis-Inducing Ligand-
dc.subject.MESHThyroid Neoplasms-
dc.subject.MESHTime Factors-
dc.subject.MESHTransfection-
dc.subject.MESHValproic Acid-
dc.subject.MESHbcl-X Protein-
dc.titleDownregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL-
dc.typeArticle-
dc.identifier.pmid26721202-
dc.contributor.affiliatedAuthor이, 복순-
dc.contributor.affiliatedAuthor한, 재호-
dc.contributor.affiliatedAuthor신, 유섭-
dc.contributor.affiliatedAuthor김, 철호-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.canlet.2015.12.016-
dc.citation.titleCancer letters-
dc.citation.volume372-
dc.citation.number1-
dc.citation.date2016-
dc.citation.startPage65-
dc.citation.endPage74-
dc.identifier.bibliographicCitationCancer letters, 372(1). : 65-74, 2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1872-7980-
dc.relation.journalidJ003043835-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Otolaryngology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse